A team at the USC Center for Personalized Brain Health has identified a pathway that may allow brain inflammation to be switched off before it causes damage. The group, led by center director Hussein Yassine, MD, focused on a family of enzymes tied to inflammation risk in people who carry the APOE4 gene variation, the strongest known genetic risk factor for late-onset Alzheimer's. By activating or inhibiting those enzymes, the researchers found a route worth pursuing for prevention rather than treatment after symptoms appear.
The distinction matters. Most Alzheimer's drug development has aimed at people who already have measurable disease, when much of the underlying injury has been building for years. Work aimed at inflammation in APOE4 carriers, who face elevated risk long before any cognitive change, points toward intervening while the brain is still intact - and toward the kind of personalized approach that matches a therapy to a person's genetic profile.
The effort has new financial backing. The Norman and Mary Pattiz Foundation has given $3 million to the Keck School of Medicine of USC, creating the Norman and Mary Pattiz Alzheimer's Research Fund. The money will provide pilot funding and speed up priority projects at the USC Alzheimer's Disease Research Center, covering drug targeting and imaging development, the use of artificial intelligence to identify small molecules involved in brain inflammation, modernization of the center's brain pathology library, and studies of inflammation markers in patients who already have Alzheimer's.
This remains early-stage science: a promising pathway is not a drug, and the fund is explicitly aimed at pilot projects and discovery work. What it signals is where a growing share of Alzheimer's research energy is heading - away from waiting for symptoms, and toward detection and prevention in people whose genetics put them at higher risk.